MedTrace Logo

Ecopipam Treatment of Tourette Syndrome

NCT01244633 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-09-29

Study results available
· View outcomes & findings →

Summary

Tourette's Syndrome is a neurological disease characterized by verbal and motor tics. The currently available drug treatments are considered to be inadequate. This clinical trial is designed to test if ecopipam is effective for the treatment of Tourette's Syndrome in adults.

Conditions

  • Tourette's Syndrome

Interventions

DRUG

Ecopipam

50 or 100 mg tablets given once per day for eight weeks

Sponsors & Collaborators

  • Psyadon Pharma

    lead INDUSTRY

Principal Investigators

  • Donald Gilbert, MD · Children's Hospital Medical Center, Cincinnati

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-07-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01244633 on ClinicalTrials.gov